Qbiotics, page-571

Yes, a little disappointing. However, reports does say covid has had a severe impact on revenue, due to limitations placed on marketing, sales, training vets etc. Also impacting hugely on human trials. Hoping for better things to come. Wish we knew how those being treated are progressing. Also glad to hear a couple of people have been treated through the Special Access Scheme. Though again we don't know how they fared.

Promising results with initial Vet trials on STC. 50% complete response with 14% partial and looking at modifying treatment to aim for better results. 50% with cancer is always good. Building a solid foundation.